TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception
In the last decade, considerable evidence as accumulated to support the development of Transient Receptor Potential Vanilloid 1 (TRPV1) antagonists for the treatment of various chronic pain conditions. Whereas there is a widely accepted rationale for the development of TRPV1 antagonists for the trea...
Main Authors: | Michael R. Brandt, Chad E. Beyer, Stephen M. Stahl |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2012-02-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/5/2/114/ |
Similar Items
-
TRPV1: A Target for Rational Drug Design
by: Vincenzo Carnevale, et al.
Published: (2016-08-01) -
Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials
by: Michael J. Iadarola, et al.
Published: (2021-08-01) -
Paclitaxel Induces Upregulation of Transient Receptor Potential Vanilloid 1 Expression in the Rat Spinal Cord
by: Yukako Kamata, et al.
Published: (2020-06-01) -
Cytoplasmic Inter-Subunit Interface Controls Use-Dependence of Thermal Activation of TRPV3 Channel
by: Lucie Macikova, et al.
Published: (2019-08-01) -
Itch induced by peripheral mu opioid receptors is dependent on TRPV1-expressing neurons and alleviated by channel activation
by: Helvira Melo, et al.
Published: (2018-10-01)